What is Aura Biosciences, Inc. (AURA)?

Aura Biosciences, Inc. (AURA) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of AURA?

The current price of AURA is $6.40. Prices are updated in real time on Stocks360.

What is AURA's price-to-earnings (PE) ratio?

AURA's trailing twelve-month PE ratio is -3.60, based on current price and earnings per share data available on Stocks360.

What is AURA's market capitalization?

AURA's market capitalization is $663,710,778.00, placing it in the small-cap tier.

Aura Biosciences, Inc. (AURA)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$6.40

Market Cap

$663.71M

PE (TTM)

-3.60

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.41

Day Range

$6.23 – $6.41

52-wk Range

$4.73 – $9.54

Avg Volume

N/A

Volume

541.81K

Aura Biosciences, Inc. (AURA) is a publicly traded company in the Healthcare sector. Latest price: $6.40. Market cap $663.71M. Trailing PE -3.60. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-29 · $6.14 2026-10-28 · $6.40 (+4.23%)

Earnings

Most Recent

Aug 11, 2026

EPS $-0.48 vs est. $-0.38

Missed by $0.10

Next Earnings

Nov 5, 2026

EPS estimate $-0.37

Proprietary Signals

Signal snapshot temporarily unavailable.

About Aura Biosciences, Inc.

Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-3.60×
P/S (TTM)	0.00×
P/B	1.93×
P/FCF (TTM)	-6.47×
EV / EBITDA	-4.63×
EV / Sales	0.00×
Earnings Yield	-21.58%
Free Cash Flow Yield	-15.47%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$612.47M
Net Income (TTM)	-$143.22M
Free Cash Flow (TTM)	-$102.65M
Net Debt	-$51.24M
Working Capital	$309.47M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-73.18%
Return on Invested Capital	-41.61%